<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZIDOVUDINE- zidovudine capsule </strong><br>Edenbridge Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Zidovudine safely and effectively. See full prescribing information for Zidovudine.<br><br> Initial U.S. Approval: 1987</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF HEMATOLOGICAL TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>.</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been associated with the use of zidovudine. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including zidovudine. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. (<a href="#S5.3">5.3</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> (<a href="#S5.6">5.6</a>)     (11/2011) </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF HEMATOLOGICAL TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>.</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been associated with the use of zidovudine. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> associated with prolonged use of zidovudine. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including zidovudine. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. (<a href="#S5.3">5.3</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Zidovudine is a nucleoside analogue reverse transcriptase inhibitor indicated for: </p>
<ul>
<li> Treatment of Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in combination with other antiretroviral agents. (<a href="#S1.1">1.1</a>)</li>
<li> Prevention of maternal-fetal HIV-1 transmission. (<a href="#S1.2">1.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:<dl>
<dt> </dt>
<dd>Adults: 600 mg/day in divided doses with other antiretroviral agents.</dd>
<dt> </dt>
<dd>Pediatric patients (aged 4 weeks to &lt;18 years): Dosage should be calculated based on body weight not to exceed adult dose. (<a href="#S2.1">2.1</a>)</dd>
</dl>
</li>
<li>Prevention of maternal-fetal HIV-1 transmission:<dl>
<dt> </dt>
<dd>Specific dosage instructions for mother and infant. (<a href="#S2.2">2.2</a>)</dd>
</dl>
</li>
<li>Patients with severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and/or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>:<dl>
<dt> </dt>
<dd>Dosage interruption may be necessary. (<a href="#S2.3">2.3</a>)</dd>
</dl>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Recommended dosage in hemodialysis or peritoneal dialysis patients is 100 mg every 6 to 8 hours. (<a href="#S2.4">2.4</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 100 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="Bold">­</span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to zidovudine (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>). (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> See<a href="#BOX"> boxed warning </a>for information about the following: hematologic toxicity, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> (<a href="#S5.1">5.1</a>,<a href="#S5.2"> 5.2</a>,<a href="#S5.3"> 5.3</a>)</li>
<li> Exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine.<dl>
<dt> </dt>
<dd>Coadministration of ribavirin and zidovudine is not advised. (<a href="#S5.4">5.4</a>)</dd>
</dl>
</li>
<li> Hepatic decompensation, (some fatal), has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin. Discontinue zidovudine as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. (<a href="#S5.4">5.4</a>)</li>
<li> Zidovudine should not be administered with other zidovudine-containing combination products. (<a href="#S5.5">5.5</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> (<a href="#S5.6">5.6</a>) and redistribution/accumulation of body fat (<a href="#S5.7">5.7</a>) have been reported in patients treated with combination antiretroviral therapy.</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li> Most commonly reported adverse reactions (incidence ≥15%) in adult HIV-1 clinical studies were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#S6.1">6.1</a>)</li>
<li> Most commonly reported adverse reactions (incidence ≥15%) in pediatric HIV-1 clinical studies were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and digestive disorders. (<a href="#S6.1">6.1</a>)</li>
<li> Most commonly reported adverse reactions in neonates (incidence ≥15%) in the prevention of maternal-fetal transmission of HIV-1 clinical trial were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. (<a href="#S6.1">6.1</a>)</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or  FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Stavudine: Concomitant use with zidovudine should be avoided. (<a href="#S7.1">7.1</a>)</li>
<li>Doxorubicin: Use with zidovudine should be avoided. (<a href="#S7.2">7.2</a>)</li>
<li>Bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (<a href="#S7.3">7.3</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">­Pregnancy: Physicians are encouraged to register patients in the Antiretroviral Pregnancy Registry by calling 1-800-258-4263. (<a href="#S8.1">8.1</a>) </p></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: RISK OF HEMATOLOGICAL TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Treatment of HIV-1</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Prevention of Maternal-Fetal HIV-1 Transmission</a></h2>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Prevention of Maternal-Fetal HIV-1 Transmission</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients With Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> and/or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hematologic Toxicity/Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use With Interferon- and Ribavirin-Based Regimens in HIV-1/HCV Co-Infected Patients</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Use With Other Zidovudine-Containing Products</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Fat Redistribution</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antiretroviral Agents</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Doxorubicin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Reproductive and Developmental Toxicology Studies</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Patients</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Prevention of Maternal-Fetal HIV-1 Transmission</a></h2>
<h1><a href="#section-14" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Advice for the Patient</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: RISK OF HEMATOLOGICAL TOXICITY, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">MYOPATHY</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></h1>
<p class="First"><span class="Bold">Hematologic Toxicity: Zidovudine Capsules have been associated with hematologic toxicity including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, particularly in patients with advanced HIV-1 disease<span class="Italics"> [see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>: Prolonged use of zidovudine has been associated with symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span><span class="Italics"> [see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur<span class="Italics"> [see<a href="#S5.3"> Warnings and Precautions (5.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Treatment of HIV-1</h2>
<p class="First">Zidovudine, a nucleoside reverse transcriptase inhibitor, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Prevention of Maternal-Fetal HIV-1 Transmission</h2>
<p class="First">Zidovudine is indicated for the prevention of maternal-fetal HIV-1 transmission <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>. The indication is based on a dosing regimen that included 3 components:</p>
<ol class="Arabic">
<li>antepartum therapy of HIV-1 infected mothers</li>
<li>intrapartum therapy of HIV-1 infected mothers</li>
<li>post-partum therapy of HIV-1 exposed neonate.</li>
</ol>
<p>Points to consider prior to initiating Zidovudine in pregnant women for the prevention of maternal-fetal HIV-1 transmission include:</p>
<ul>
<li>  In most cases, Zidovudine for prevention of maternal-fetal HIV-1 transmission should be given in combination with other antiretroviral drugs.</li>
<li>  Prevention of HIV-1 transmission in women who have received Zidovudine for a prolonged period before pregnancy has not been evaluated.</li>
<li>  Because the fetus is most susceptible to the potential teratogenic effects of drugs during the first 10 weeks of gestation and the risks of therapy with Zidovudine during that period are not fully known, women in the first trimester of pregnancy who do not require immediate initiation of antiretroviral therapy for their own health may consider delaying use; this indication is based on use after 14 weeks gestation.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span>: The recommended oral dose of zidovudine is 600 mg/day in divided doses in combination with other antiretroviral agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Underline">Pediatric Patients (Aged 4 Weeks to &lt;18 Years)</span>: Healthcare professionals should pay special attention to accurate calculation of the dose of Zidovudine, transcription of the  medication order, dispensing information, and dosing instructions to minimize risk for  medication dosing errors.</p>
<p>Prescribers should calculate the appropriate dose of zidovudine for each child based on body weight (kg) and should not exceed the recommended adult dose.</p>
<p>Before prescribing Zidovudine capsules, children should be assessed for the ability to swallow capsules. If a child is unable to reliably swallow a Zidovudine capsule, the Zidovudine syrup formulation should be prescribed.</p>
<p>The recommended dosage in pediatric patients 4 weeks of age and older and weighing ≥4 kg is provided in Table 1. Zidovudine syrup should be used to provide accurate dosage when whole tablets or capsules are not appropriate.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Recommended Pediatric Dosage of Zidovudine</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Body Weight (kg)</th>
<th class="Rrule" align="center" rowspan="2">Total Daily Dose</th>
<th class="Rrule" align="center" colspan="2">Dosage Regimen and Dose</th>
</tr>
<tr class="Botrule Last">
<th class="Rrule" align="center">Twice Daily</th>
<th class="Rrule" align="center">Three Times Daily</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">4 to &lt;9</td>
<td class="Rrule" align="left">24 mg/kg/day</td>
<td class="Rrule" align="center">12 mg/kg</td>
<td class="Rrule" align="center">8 mg/kg</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">≥ 9 to &lt;30</td>
<td class="Rrule" align="left">18 mg/kg/day</td>
<td class="Rrule" align="center">9 mg/kg</td>
<td class="Rrule" align="center">6 mg/kg</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">≥ 30</td>
<td class="Rrule" align="left">600 mg/day</td>
<td class="Rrule" align="center">300 mg</td>
<td class="Rrule" align="center">200 mg</td>
</tr>
</tbody>
</table>
<p>Alternatively, dosing for zidovudine can be based on body surface area (BSA) for each child. The recommended oral dose of zidovudine is 480 mg/m<span class="Sup">2</span>/day in divided doses (240 mg/m<span class="Sup">2</span> twice daily or 160 mg/m<span class="Sup">2</span> three times daily). In some cases the dose calculated by mg/kg will not be the same as that calculated by BSA.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Prevention of Maternal-Fetal HIV-1 Transmission</h2>
<p class="First">The recommended dosage regimen for administration to pregnant women (&gt;14 weeks of pregnancy) and their neonates is:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline">Maternal Dosing</span>: 100 mg orally 5 times per day until the start of labor <span class="Italics">[see<a href="#S14.3"> Clinical Studies (14.3)</a>]</span>. During labor and delivery, intravenous Zidovudine should be administered at 2 mg/kg (total body weight) over 1 hour followed by a continuous intravenous infusion of 1 mg/kg/hour (total body weight) until clamping of the umbilical cord.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Underline">Neonatal Dosing</span>: 2 mg/kg orally every 6 hours starting within 12 hours after birth and continuing through 6 weeks of age. Neonates unable to receive oral dosing may be administered zidovudine intravenously at 1.5 mg/kg, infused over 30 minutes, every 6 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients With Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> and/or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">Significant <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (hemoglobin &lt;7.5 g/dL or reduction &gt;25% of baseline) and/or significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (granulocyte count &lt;750 cells/mm<span class="Sup">3</span> or reduction &gt;50% from baseline) may require a dose interruption until evidence of marrow recovery is observed <span class="Italics">[see<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>. In patients who develop significant <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, dose interruption does not necessarily eliminate the need for transfusion. If marrow recovery occurs following dose interruption, resumption in dose may be appropriate using adjunctive measures such as epoetin alfa at recommended doses, depending on hematologic indices such as serum erythropoetin level and patient tolerance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Underline">End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span>: In patients maintained on hemodialysis or peritoneal dialysis, the recommended dosage is 100 mg every 6 to 8 hours <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Patients With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">There are insufficient data to recommend dose adjustment of Zidovudine in patients with mild to moderate impaired hepatic function or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Zidovudine Capsules USP, 100mg are hard gelatin size '2' capsules with sky blue cap and white body, straight printed with 'ZVR 100'on both cap and body with black ink.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Zidovudine Capsules are contraindicated in patients who have had potentially life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) to any of the components of the formulations.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hematologic Toxicity/Bone Marrow Suppression</h2>
<p class="First">Zidovudine should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count &lt;1,000 cells/mm<span class="Sup">3</span> or hemoglobin &lt;9.5 g/dL. Hematologic toxicities appear to be related to pretreatment bone marrow reserve and to dose and duration of therapy. In patients with advanced symptomatic HIV-1 disease, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> were the most significant adverse events observed. In patients who experience hematologic toxicity, a reduction in hemoglobin may occur as early as 2 to 4 weeks, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> usually occurs after 6 to 8 weeks. There have been reports of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> associated with the use of zidovudine, which was reversible in most instances after discontinuance of the drug. However, significant <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, in many cases requiring dose adjustment, discontinuation of zidovudine, and/or blood transfusions, has occurred during treatment with zidovudine alone or in combination with other antiretrovirals.</p>
<p>Frequent blood counts are strongly recommended to detect severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in patients with poor bone marrow reserve, particularly in patients with advanced HIV-1 disease who are treated with zidovudine. For HIV-1-infected individuals and patients with asymptomatic or early HIV-1 disease, periodic blood counts are recommended. If <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> develops, dosage interruption may be needed <span class="Italics">[see<a href="#S2.3"> Dosage and Administration (2.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> with pathological changes, similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including zidovudine and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged exposure to antiretroviral nucleoside analogues may be risk factors. Particular caution should be exercised when administering zidovudine to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with zidovudine should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use With Interferon- and Ribavirin-Based Regimens in HIV-1/HCV Co-Infected Patients</h2>
<p class="First">In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as zidovudine. Although no evidence of a pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> (e.g., loss of HIV-1/HCV virologic suppression) was seen when ribavirin was coadministered with zidovudine in HIV-1/HCV co-infected patients <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>], exacerbation of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to ribavirin has been reported when zidovudine is part of the HIV regimen. Coadministration of ribavirin and zidovudine is not advised. Consideration should be given to replacing zidovudine in established combination HIV-1/HCV therapy, especially in patients with a known history of zidovudine-induced <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>Hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin. Patients receiving interferon alfa with or without ribavirin and zidovudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>Discontinuation of zidovudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon alfa, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Childs Pugh &gt;6) (see the complete prescribing information for interferon and ribavirin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Use With Other Zidovudine-Containing Products</h2>
<p class="First">Zidovudine should not be administered with combination products that contain zidovudine as one of their components (e.g., COMBIVIR<span class="Sup">®</span> [lamivudine and zidovudine] Tablets or TRIZIVIR<span class="Sup">®</span> [abacavir sulfate, lamivudine, and zidovudine] Tablets).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including zidovudine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Graves' disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat, including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance," have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li>Hematologic toxicity, including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>,<a href="#S5.1"> Warnings and   Precautions (5.1)</a>]</span>.</li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>,<a href="#S5.2"> Warnings and   Precautions (5.2)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>,<a href="#S5.3"> Warnings and   Precautions (5.3)</a>]</span>.</li>
<li>Hepatic decompensation in patients co-infected with HIV-1 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults:</span> The frequency and severity of adverse reactions associated with the use of zidovudine are greater in patients with more advanced <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the time of initiation of therapy.</p>
<p>Table 2 summarizes events reported at a statistically significant greater incidence for patients receiving zidovudine in a monotherapy study.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2. Percentage (%) of Patients with Adverse Reactions<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> in Asymptomatic HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> (ACTG019)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="27%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Adverse Reaction</th>
<th class="Rrule" align="center">Zidovudine 500 mg/day<br>(n = 453)</th>
<th class="Rrule" align="center">Placebo<br>(n = 428)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Reported in ≥5% of study population.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Not statistically significant versus placebo.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Body as a whole</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">9%<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">63%</td>
<td class="Rrule" align="center">53%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">53%</td>
<td class="Rrule" align="center">45%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Gastrointestinal</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">20%</td>
<td class="Rrule" align="center">11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">6%<a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">51%</td>
<td class="Rrule" align="center">30%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">17%</td>
<td class="Rrule" align="center">10%</td>
</tr>
</tbody>
</table>
<p>In addition to the adverse reactions listed in Table 2, adverse reactions observed at an incidence of ≥5% in any treatment arm in clinical studies (NUCA3001, NUCA3002, NUCB3001, and NUCB3002) were <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>. Additionally, in these studies <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> was reported at an incidence of ≤0.8%.</p>
<p>Selected laboratory abnormalities observed during a clinical study of monotherapy with zidovudine are shown in Table 3.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3. Frequencies of Selected (Grade 3/4) Laboratory Abnormalities in Patients with Asymptomatic HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> (ACTG019)</span></caption>
<col align="left" valign="top" width="43%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="24%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Test<br>(Abnormal Level)</th>
<th class="Rrule" align="center">Zidovudine 500 mg/day<br>(n = 453)</th>
<th class="Rrule" align="center">Placebo<br>(n = 428)</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">ULN = Upper limit of normal</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb&lt;8 g/dL)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span> (&lt;750 cells/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (platelets&lt;50,000/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT (&gt;5 × ULN)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AST (&gt;5 × ULN)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Pediatrics:</span> The clinical adverse reactions reported among adult recipients of zidovudine may also occur in pediatric patients.</p>
<p><span class="Italics">Study ACTG300:</span> Selected clinical adverse reactions and physical findings with a ≥5% frequency during therapy with EPIVIR<span class="Sup">®</span> (lamivudine) Oral Suspension 4 mg/kg twice daily plus zidovudine 160 mg/m<span class="Sup">2</span> 3 times daily compared with didanosine in therapy-naive (≤56 days of antiretroviral therapy) pediatric patients are listed in Table 4.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4. Selected Clinical Adverse Reactions and Physical Findings (≥5% Frequency) in Pediatric Patients in Study ACTG300</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="27%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Adverse Reaction</th>
<th class="Rrule" align="center">EPIVIR plus ziodvudine<br>(n = 236)</th>
<th class="Rrule" align="center">Didanosine<br>(n = 235)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, discharge, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of an ear</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Body as a whole</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">25%</td>
<td class="Rrule" align="center">32%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Digestive</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> &amp; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">Splenomegaly</span></td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Respiratory</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">15%</td>
<td class="Rrule" align="center">18%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">9%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Ear, Nose, and Throat</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Signs or symptoms of ears<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Nasal discharge</span> or congestion</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">11%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Other</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">14%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span></td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">11%</td>
</tr>
</tbody>
</table>
<p>Selected laboratory abnormalities experienced by therapy-naive (≤56 days of antiretroviral therapy) pediatric patients are listed in Table 5.</p>
<a name="table5"></a><table width="75%">
<caption><span>Table 5. Frequencies of Selected (Grade 3/4) Laboratory Abnormalities in Pediatric Patients in Study ACTG300</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Test<br>(Abnormal Level)</th>
<th class="Rrule" align="center">EPIVIR plus zidovudine</th>
<th class="Rrule" align="center">Didanosine</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">ULN = Upper limit of normal.</td></tr>
<tr class="Last"><td align="left" colspan="3">ANC = Absolute neutrophil count.</td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (ANC&lt;400 cells/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb&lt;7.0 g/dL)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (platelets&lt;50,000/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT (&gt;10 × ULN)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST (&gt;10 × ULN)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lipase (&gt;2.5 × ULN)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Total amylase (&gt;2.5 × ULN)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">Macrocytosis</span> was reported in the majority of pediatric patients receiving zidovudine 180 mg/m<span class="Sup">2</span> every 6 hours in open-label studies. Additionally, adverse reactions reported at an  incidence of &lt;6% in these studies were <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, decreased reflexes, ECG abnormality, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, left ventricular dilation, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>/<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Use for the Prevention of Maternal-Fetal Transmission of HIV-1</span>: In a randomized, double-blind, placebo-controlled trial in HIV-1-infected women and their neonates conducted to determine the utility of zidovudine for the prevention of maternal-fetal HIV-1 transmission, zidovudine syrup at 2 mg/kg was administered every 6 hours for 6 weeks to neonates beginning within 12 hours following birth. The most commonly reported adverse reactions were <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (hemoglobin &lt;9.0 g/dL) and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (&lt;1,000 cells/mm<span class="Sup">3</span>). <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> occurred in 22% of the neonates who received zidovudine and in 12% of the neonates who received placebo. The mean difference in hemoglobin values was less than 1.0 g/dL for neonates receiving zidovudine compared with neonates receiving placebo. No neonates with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> required transfusion and all hemoglobin values spontaneously returned to normal within 6 weeks after completion of therapy with zidovudine. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> in neonates was reported with similar frequency in the group that received zidovudine (21%) and in the group that received placebo (27%). The long-term consequences of in utero and infant exposure to zidovudine are unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of zidovudine. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to zidovudine.</p>
<p><span class="Underline">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, flu-like syndrome, generalized <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, redistribution/accumulation of body fat <span class="Italics">[see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>.</p>
<p><span class="Underline">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Underline">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>.</p>
<p><span class="Underline">Eye:</span> <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>.</p>
<p><span class="Underline">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, oral mucosa <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcer</span>.</p>
<p><span class="Underline">General:</span> Sensitization reactions including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Underline">Hemic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>.</p>
<p><span class="Underline">Hepatobiliary Tract and Pancreas:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Underline">Musculoskeletal:</span> Increased CPK, increased LDH, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> with pathological changes (similar to that produced by HIV-1 disease), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p><span class="Underline">Nervous:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of mental acuity, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Underline">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
<p><span class="Underline">Skin:</span> Changes in skin and <span class="product-label-link" type="condition" conceptid="4297821" conceptname="Melanonychia">nail pigmentation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, sweat, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Underline">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
<p><span class="Underline">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Antiretroviral Agents</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Underline">Stavudine:</span> Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated in vitro.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Underline">Nucleoside Analogues Affecting DNA Replication:</span> Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the in vitro antiviral activity of zidovudine against HIV-1; concomitant use of such drugs should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Doxorubicin</h2>
<p class="First">Concomitant use of zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated in vitro.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents</h2>
<p class="First">Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C.</p>
<p>In humans, treatment with zidovudine during pregnancy reduced the rate of maternal-fetal HIV-1 transmission from 24.9% for infants born to placebo-treated mothers to 7.8% for infants born to mothers treated with zidovudine <span class="Italics">[see<a href="#S14.3"> Clinical Studies (14.3)</a>]</span>. There were no differences in pregnancy-related adverse events between the treatment groups. Animal reproduction studies in rats and rabbits showed evidence of embryotoxicity and increased <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>.</p>
<p>A randomized, double-blind, placebo-controlled trial was conducted in HIV-1-infected pregnant women to determine the utility of zidovudine for the prevention of maternal-fetal HIV-1-transmission <span class="Italics">[see<a href="#S14.3"> Clinical Studies (14.3)</a>]</span>. Congenital abnormalities occurred with similar frequency between neonates born to mothers who received zidovudine and neonates born to mothers who received placebo. The observed abnormalities included problems in embryogenesis (prior to 14 weeks) or were recognized on ultrasound before or immediately after initiation of study drug.</p>
<p>Increased fetal resorptions occurred in pregnant rats and rabbits treated with doses of zidovudine that produced drug plasma concentrations 66 to 226 times (rats) and 12 to 87 times (rabbits) the mean steady-state peak human plasma concentration following a single 100-mg dose of zidovudine. There were no other reported developmental anomalies. In another developmental toxicity study, pregnant rats received zidovudine up to near-lethal doses that produced peak plasma concentrations 350 times peak human plasma concentrations (300 times the daily exposure [AUC] in humans given 600 mg/day zidovudine). This dose was associated with marked maternal toxicity and an increased incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. However, there were no signs of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at doses up to one fifth the lethal dose <span class="Italics">[see<a href="#S13.2"> Nonclinical Toxicology (13.2)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Underline">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to zidovudine, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Zidovudine is excreted in human milk <span class="Italics">[see<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving zidovudine.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Zidovudine has been studied in HIV-1-infected pediatric patients ≥6 weeks of age who had HIV-1-related symptoms or who were asymptomatic with abnormal laboratory values indicating significant HIV-1-related <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. Zidovudine has also been studied in neonates perinatally exposed to HIV-1 <span class="Italics">[see<a href="#S2.1"> Dosage and Administration (2.1)</a>,<a href="#S6.1"> Adverse Reactions (6.1)</a>,<a href="#S12.3"> Clinical Pharmacology (12.3)</a>,<a href="#S14.2"> Clinical Studies (14.2)</a>,<a href="#S14.3"> (14.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of zidovudine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (CrCl&lt;15 mL/min), dosage reduction is recommended <span class="Italics">[see<a href="#S2.4"> Dosage and Administration (2.4)</a>,<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Zidovudine is eliminated from the body primarily by renal excretion following metabolism in the liver (glucuronidation). Although the data are limited, zidovudine concentrations appear to be increased in patients with severely impaired hepatic function, which may increase the risk of hematologic toxicity <span class="Italics">[see<a href="#S2.5"> Dosage and Administration (2.5)</a>,<a href="#S12.3"> Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute overdoses</span> of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50 grams. No specific symptoms or signs have been identified following acute overdosage with zidovudine apart from those listed as adverse events such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and occasional reports of hematological disturbances. All patients recovered without permanent sequelae. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine while elimination of its primary metabolite, 3'- azido-3'-deoxy-5'-<span class="Italics">O</span>-β-<span class="Italics">D</span>-glucopyranuronosylthymidine (GZDV), is enhanced.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Zidovudine (formerly called azidothymidine [AZT]) is a pyrimidine nucleoside analogue active against HIV-1. The chemical name of zidovudine is 3'-azido-3'-deoxythymidine; it has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3c2532a-5880-4d52-b2a1-2e6d4dbd6021&amp;name=zidovudine-01.jpg"></p>
<p>Zidovudine is a white to beige, odorless, crystalline solid with a molecular weight of 267.24 and a solubility of 20.1 mg/mL in water at 25°C. The molecular formula is C<span class="Sub">10</span>H<span class="Sub">13</span>N<span class="Sub">5</span>O<span class="Sub">4</span>.</p>
<p>Zidovudine Capsules are for oral administration. Each capsule contains 100 mg of zidovudine and the inactive ingredients microcrystalline cellulose, sodium starch glycolate, corn starch, colloidal silicon dioxide, talc &amp; magnesium stearate. The empty hard gelatin capsule printed with edible black ink consist of  black iron oxide, shellac, propylene glycol, potassium hydroxide, gelatin,  sodium lauryl sulfate, titanium dioxide, FD &amp; C blue 1.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Zidovudine is an antiviral agent <span class="Italics">[see<a href="#S12.4"> Clinical Pharmacology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Absorption and Bioavailability:</span> In adults, following oral administration, zidovudine is rapidly absorbed and extensively distributed, with peak serum concentrations occurring within 0.5 to 1.5 hours. The AUC was equivalent when zidovudine was administered as zidovudine tablets or syrup compared with zidovudine capsules. The pharmacokinetic properties of zidovudine in fasting adult patients are summarized in Table 6.</p>
<a name="table6"></a><table width="75%">
<caption><span>Table 6. Zidovudine Pharmacokinetic Parameters in Fasting Adult Patients</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Parameter</th>
<th class="Rrule" align="center">Mean ± SD<br>(except where noted)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Median [range].</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Approximate range.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Oral bioavailability (%)</td>
<td class="Rrule" align="center">64 ± 10<br>(n = 5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Apparent volume of distribution (L/kg)</td>
<td class="Rrule" align="center">1.6 ± 0.6<br>(n = 8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Plasma protein binding (%)</td>
<td class="Rrule" align="center">&lt;38</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CSF: plasma ratio<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">0.6 [0.04 to 2.62]<br>(n = 39)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Systemic clearance (L/hr/kg)</td>
<td class="Rrule" align="center">1.6 ± 0.6<br>(n = 6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Renal clearance (L/hr/kg)</td>
<td class="Rrule" align="center">0.34 ± 0.05<br>(n = 9)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Elimination half-life (hr)<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.5 to 3<br>(n = 19)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Distribution:</span> The apparent volume of distribution of zidovudine, following oral administration, is 1.6 ± 0.6 L/kg; and binding to plasma protein is low, &lt;38% (Table 6).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism and Elimination:</span> Zidovudine is primarily eliminated by hepatic metabolism. The major metabolite of zidovudine is GZDV. GZDV AUC is about 3-fold greater than the zidovudine AUC. Urinary recovery of zidovudine and GZDV accounts for 14% and 74%, respectively, of the dose following oral administration. A second metabolite, 3'-amino-3'-deoxythymidine (AMT), has been identified in the plasma following single-dose intravenous (IV) administration of zidovudine. The AMT AUC was one fifth of the zidovudine AUC. Pharmacokinetics of zidovudine were dose independent at oral dosing regimens ranging from 2 mg/kg every 8 hours to 10 mg/kg every 4 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline">Effect of Food on Absorption:</span> Zidovudine may be administered with or without food. The zidovudine AUC was similar when a single dose of zidovudine was administered with food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Underline">Special Populations: </span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Zidovudine clearance was decreased resulting in increased zidovudine and GZDV half-life and AUC in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (n = 14) following a single 200-mg oral dose (Table 7). Plasma concentrations of AMT were not determined. A dose adjustment should not be necessary for patients with creatinine clearance (CrCl) ≥15 mL/min.</p>
<a name="table7"></a><table width="75%">
<caption><span>Table 7. Zidovudine Pharmacokinetic Parameters in Patients With Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Parameter</th>
<th class="Rrule" align="center">Control Subjects<br>(Normal Renal Function)<br>(n = 6)</th>
<th class="Rrule" align="center">Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>(n = 14)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Data are expressed as mean ± standard deviation.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">CrCl (mL/min)</td>
<td class="Rrule" align="center">120 ± 8</td>
<td class="Rrule" align="center">18 ± 2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Zidovudine AUC (ng∙hr/mL)</td>
<td class="Rrule" align="center">1,400 ± 200</td>
<td class="Rrule" align="center">3,100 ± 300</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Zidovudine half-life (hr)</td>
<td class="Rrule" align="center">1.0 ± 0.2</td>
<td class="Rrule" align="center">1.4 ± 0.1</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.1"></a><p></p>
<p class="First"><span class="Italics">Hemodialysis and Peritoneal Dialysis:</span> The pharmacokinetics and tolerance of zidovudine were evaluated in a multiple-dose study in patients undergoing hemodialysis (n = 5) or peritoneal dialysis (n = 6) receiving escalating doses up to 200 mg 5 times daily for 8 weeks. Daily doses of 500 mg or less were well tolerated despite significantly elevated GZDV plasma concentrations. Apparent zidovudine oral clearance was approximately 50% of that reported in patients with normal renal function. Hemodialysis and peritoneal dialysis appeared to have a negligible effect on the removal of zidovudine, whereas GZDV elimination was enhanced. A dosage adjustment is recommended for patients undergoing hemodialysis or peritoneal dialysis <span class="Italics">[see<a href="#S2.4"> Dosage and Administration (2.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Data describing the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of zidovudine are limited. However, because zidovudine is eliminated primarily by hepatic metabolism, it is expected that zidovudine clearance would be decreased and plasma concentrations would be increased following administration of the recommended adult doses to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see<a href="#S2.5"> Dosage and Administration (2.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.3"></a><p></p>
<p class="First"><span class="Italics">Pediatrics Patients:</span> Zidovudine pharmacokinetics have been evaluated in HIV-1-infected pediatric patients (Table 8).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.4"></a><p></p>
<p class="First"><span class="Italics">Patients Aged 3 Months to 12 Years:</span> Overall, zidovudine pharmacokinetics in pediatric patients greater than 3 months of age are similar to those in adult patients. Proportional increases in plasma zidovudine concentrations were observed following administration of oral solution from 90 to 240 mg/m<span class="Sup">2</span> every 6 hours. Oral bioavailability, terminal half-life, and oral clearance were comparable to adult values. As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged, and about 45% of the dose was excreted as GZDV <span class="Italics">[see<a href="#S2.1"> Dosage and Administration (2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.5"></a><p></p>
<p class="First"><span class="Italics">Patients Aged Less Than 3 Months:</span> Zidovudine pharmacokinetics have been evaluated in pediatric patients from birth to 3 months of life. Zidovudine elimination was determined immediately following birth in 8 neonates who were exposed to zidovudine in utero. The half-life was 13.0 ± 5.8 hours. In neonates ≤14 days old, bioavailability was greater, total body clearance was slower, and half-life was longer than in pediatric patients &gt;14 days old. For dose recommendations for neonates, <span class="Italics">[see<a href="#S2.2"> Dosage and Administration (2.2)</a>]</span>.</p>
<a name="table8"></a><table width="75%">
<caption><span>Table 8. Zidovudine Pharmacokinetic Parameters in Pediatric Patients<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Parameter</th>
<th class="Rrule" align="center" valign="middle">Birth to 14 Days of Age</th>
<th class="Rrule" align="center">Aged  14 Days to 3 Months of Age</th>
<th class="Rrule" align="center">Aged  3 Months to 12 Years of Age</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Data presented as mean ± standard deviation except where noted.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Median [range]</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Oral bioavailability (%)</td>
<td class="Rrule" align="center">89 ± 19<br>(n = 15)</td>
<td class="Rrule" align="center">61 ± 19<br>(n = 17)</td>
<td class="Rrule" align="center">65 ± 24<br>(n = 18)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CSF:plasma ratio</td>
<td class="Rrule" align="center">No data</td>
<td class="Rrule" align="center">No data</td>
<td class="Rrule" align="center">0.68 [0.03 to 3.25]<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a><br>(n = 38)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CL (L/hr/kg)</td>
<td class="Rrule" align="center">0.65 ± 0.29<br>(n = 18)</td>
<td class="Rrule" align="center">1.14 ± 0.24<br>(n = 16)</td>
<td class="Rrule" align="center">1.85 ± 0.47<br>(n = 20)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Elimination half-life (hr)</td>
<td class="Rrule" align="center">3.1 ± 1.2<br>(n = 21)</td>
<td class="Rrule" align="center">1.9 ± 0.7<br>(n = 18)</td>
<td class="Rrule" align="center">1.5 ± 0.7<br>(n = 21)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.6"></a><p></p>
<p class="First"><span class="Italics">Pregnancy:</span> Zidovudine pharmacokinetics have been studied in a Phase I study of 8 women during the last trimester of pregnancy. Zidovudine pharmacokinetics were similar to those of nonpregnant adults. Consistent with passive transmission of the drug across the placenta, zidovudine concentrations in neonatal plasma at birth were essentially equal to those in maternal plasma at delivery <span class="Italics">[see<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>.</p>
<p>Although data are limited, methadone maintenance therapy in 5 pregnant women did not appear to alter zidovudine pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.7"></a><p></p>
<p class="First"><span class="Italics">Nursing Mothers:</span> The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. After administration of a single dose of 200 mg zidovudine to 13 HIV-1-infected women, the mean concentration of zidovudine was similar in human milk and serum <span class="Italics">[see<a href="#S8.3"> Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.8"></a><p></p>
<p class="First"><span class="Italics">Geriatric Patients:</span> Zidovudine pharmacokinetics have not been studied in patients over 65 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5.9"></a><p></p>
<p class="First"><span class="Italics">Gender:</span> A pharmacokinetic study in healthy male (n = 12) and female (n = 12) subjects showed no differences in zidovudine AUC when a single dose of zidovudine was administered as the 300-mg zidovudine tablet.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions: </span><span class="Italics">[See<a href="#S7"> Drug Interactions (7)</a>]</span>.</p>
<a name="table9"></a><table width="100%">
<caption><span>Table 9. Effect of Co-administered Drugs on Zidovudine AUC<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="24%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="24%">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="left" colspan="6" valign="top">Note: ROUTINE DOSE MODIFICATION OF ZIDOVUDINE IS NOT WARRANTED WITH COADMINISTRATION OF THE FOLLOWING DRUGS</th></tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center" rowspan="2">Coadministered Drug and Dose<br>
</th>
<th class="Rrule" align="center" rowspan="2">Zidovudine Dose<br><br>
</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">n</th>
<th class="Rrule" align="center" colspan="2">Zidovudine<br>Concentrations</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">Concentration of Coadministered Drug</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">Variability</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">↑ = Increase; ↓ = Decrease; ↔ = no significant change; AUC = area under the concentration versus time curve; CI = confidence interval.</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>This table is not all inclusive.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Estimated range of percent difference.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Atovaquone<br>750 mg q 12 hr with food</td>
<td class="Rrule" align="center">200 mg q 8 hr</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑AUC<br>31%</td>
<td class="Rrule" align="center">Range<br>23% to 78%<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</td>
<td class="Rrule" align="center">↔</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clarithromycin<br>500 mg twice daily</td>
<td class="Rrule" align="center">100 mg q 4 hr<br> × 7 days</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">↓AUC<br>12%</td>
<td class="Rrule" align="center">Range<br>↓34% to ↑14%</td>
<td class="Rrule" align="center">Not Reported</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fluconazole<br>400 mg daily</td>
<td class="Rrule" align="center">200 mg q 8 hr</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↑AUC<br>74%</td>
<td class="Rrule" align="center">95% CI:<br>54% to 98%</td>
<td class="Rrule" align="center">Not Reported</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lamivudine 300 mg q 12 hr</td>
<td class="Rrule" align="center">single 200 mg</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↑AUC<br>13%</td>
<td class="Rrule" align="center">90% CI:<br>2% to 27%</td>
<td class="Rrule" align="center">↔</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Methadone<br>30 to 90 mg daily</td>
<td class="Rrule" align="center">200 mg q 4 hr</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">↑AUC<br>43%</td>
<td class="Rrule" align="center">Range<br>16% to 64%<a href="#footnote-10" class="Sup">†</a>
</td>
<td class="Rrule" align="center">↔</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nelfinavir<br>750 mg q 8 hr × 7 to 10 days</td>
<td class="Rrule" align="center">single 200 mg</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">↓AUC<br>35%</td>
<td class="Rrule" align="center">Range<br>28% to 41%</td>
<td class="Rrule" align="center">↔</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Probenecid<br>500 mg q 6 hr × 2 days</td>
<td class="Rrule" align="center">2 mg/kg q 8 hr × 3 days</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">↑AUC<br>106%</td>
<td class="Rrule" align="center">Range<br>100% to 170%<a href="#footnote-10" class="Sup">†</a>
</td>
<td class="Rrule" align="center">Not Assessed</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Rifampin<br>600 mg daily × 14 days</td>
<td class="Rrule" align="center">200 mg q 8 hr × 14 days</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">↓AUC<br>47%</td>
<td class="Rrule" align="center">90% CI:<br>41% to 53%</td>
<td class="Rrule" align="center">Not Assessed</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir<br>300 mg q 6 hr × 4 days</td>
<td class="Rrule" align="center">200 mg q 8 hr × 4 days</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">↓AUC<br>25%</td>
<td class="Rrule" align="center">95% CI:<br>15% to 34%</td>
<td class="Rrule" align="center">↔</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Valproic acid<br>250 mg or 500 mg q 8 hr × 4 days</td>
<td class="Rrule" align="center">100 mg q 8 hr × 4 days</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">↑AUC<br>80%</td>
<td class="Rrule" align="center">Range<br>64% to 130%<a href="#footnote-10" class="Sup">†</a>
</td>
<td class="Rrule" align="center">Not Assessed</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.1"></a><p></p>
<p class="First"><span class="Italics">Phenytoin:</span> Phenytoin plasma levels have been reported to be low in some patients receiving zidovudine, while in one case a high level was documented. However, in a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> study in which 12 HIV-1-positive volunteers received a single 300-mg phenytoin dose alone and during steady-state zidovudine conditions (200 mg every 4 hours), no change in phenytoin kinetics was observed. Although not designed to optimally assess the effect of phenytoin on zidovudine kinetics, a 30% decrease in oral zidovudine clearance was observed with phenytoin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.2"></a><p></p>
<p class="First"><span class="Italics">Ribavirin: </span><span class="Italics">In vitro</span> data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n = 18), stavudine (n = 10), or zidovudine (n = 6) were co-administered as part of a multi-drug regimen to HIV-1/HCV co-infected patients <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Mechanism of Action:</span> Zidovudine is a synthetic nucleoside analogue. Intracellularly, zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The principal mode of action of ZDV-TP is inhibition of reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. ZDV-TP is a weak inhibitor of the cellular DNA polymerases α and γ and has been reported to be incorporated into the DNA of cells in culture.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Antiviral Activity:</span> The antiviral activity of zidovudine against HIV-1 was assessed in a number of cell lines (including monocytes and fresh human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). The EC<span class="Sub">50</span> and EC<span class="Sub">90</span> values for zidovudine were 0.01 to 0.49 µM (1 µM = 0.27 mcg/mL) and 0.1 to 9 µM, respectively. HIV-1 from therapy-naive subjects with no mutations associated with resistance gave median EC<span class="Sub">50</span> values of 0.011 µM (range: 0.005 to 0.110 µM) from Virco (n = 92 baseline samples from COLA40263) and 0.0017 µM (0.006 to 0.0340 µM) from Monogram Biosciences (n = 135 baseline samples from ESS30009). The EC<span class="Sub">50</span> values of zidovudine against different HIV-1 clades (A-G) ranged from 0.00018 to 0.02 µM, and against HIV-2 isolates from 0.00049 to 0.004 µM. In cell culture drug combination studies, zidovudine demonstrates synergistic activity with the nucleoside reverse transcriptase inhibitors abacavir, didanosine, and lamivudine; the non-nucleoside reverse transcriptase inhibitors delavirdine and nevirapine; and the protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir; and additive activity with interferon alfa. Ribavirin has been found to inhibit the phosphorylation of zidovudine in cell culture.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Resistance</span>: Genotypic analyses of the isolates selected in cell culture and recovered from zidovudine-treated patients showed mutations in the HIV-1 RT gene resulting in 6 amino acid substitutions (M41L, D67N, K70R, L210W, T215Y or F, and K219Q) that confer zidovudine resistance. In general, higher levels of resistance were associated with greater number of amino acid substitutions. In some patients harboring zidovudine-resistant virus at baseline, phenotypic sensitivity to zidovudine was restored by 12 weeks of treatment with lamivudine and zidovudine. Combination therapy with lamivudine plus zidovudine delayed the emergence of substitutions conferring resistance to zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Cross-Resistance:</span> In a study of 167 HIV-1-infected patients, isolates (n = 2) with multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine were recovered from patients treated for ≥1 year with zidovudine plus didanosine or zidovudine plus zalcitabine. The pattern of resistance-associated amino acid substitutions with such combination therapies was different (A62V, V75I, F77L, F116Y, Q151M) from the pattern with zidovudine monotherapy, with the Q151M substitution being most commonly associated with multi-<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. The substitution at codon 151 in combination with substitutions at 62, 75, 77, and 116 results in a virus with reduced susceptibility to didanosine, lamivudine, stavudine, zalcitabine, and zidovudine. Thymidine analogue mutations (TAMs) are selected by zidovudine and confer cross-resistance to abacavir, didanosine, stavudine, tenofovir, and zalcitabine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Zidovudine was administered orally at 3 dosage levels to separate groups of mice and rats (60 females and 60 males in each group). Initial single daily doses were 30, 60, and 120 mg/kg/day in mice and 80, 220, and 600 mg/kg/day in rats. The doses in mice were reduced to 20, 30, and 40 mg/kg/day after day 90 because of treatment-related <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, whereas in rats only the high dose was reduced to 450 mg/kg/day on day 91 and then to 300 mg/kg/day on day 279.</p>
<p>In mice, 7 late-appearing (after 19 months) vaginal neoplasms (5 nonmetastasizing squamous cell carcinomas, 1 squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span>, and 1 squamous <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyp</span>) occurred in animals given the highest dose. One late-appearing squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> occurred in the vagina of a middle-dose animal. No vaginal tumors were found at the lowest dose.</p>
<p>In rats, 2 late-appearing (after 20 months), nonmetastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drug-related tumors were observed in either sex of either species.</p>
<p>At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 3 times (mouse) and 24 times (rat) the estimated human exposure at the recommended therapeutic dose of 100 mg every 4 hours.</p>
<p>It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p>Zidovudine was mutagenic in a 5178Y/TK<span class="Sup">+/-</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, positive in an <span class="Italics">in vitro</span> cell transformation assay, clastogenic in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and positive in mouse and rat micronucleus tests after repeated doses. It was negative in a cytogenetic study in rats given a single dose.</p>
<p>Zidovudine, administered to male and female rats at doses up to 7 times the usual adult dose based on body surface area, had no effect on fertility judged by conception rates.</p>
<p>Two transplacental carcinogenicity studies were conducted in mice. One study administered zidovudine at doses of 20 mg/kg/day or 40 mg/kg/day from gestation day 10 through parturition and lactation with dosing continuing in offspring for 24 months postnatally. The doses of zidovudine administered in this study produced zidovudine exposures approximately 3 times the estimated human exposure at recommended doses. After 24 months, an increase in incidence of vaginal tumors was noted with no increase in tumors in the liver or lung or any other organ in either gender. These findings are consistent with results of the standard oral carcinogenicity study in mice, as described earlier. A second study administered zidovudine at maximum tolerated doses of 12.5 mg/day or 25 mg/day (~1,000 mg/kg nonpregnant body weight or ~450 mg/kg of term body weight) to pregnant mice from days 12 through 18 of gestation. There was an increase in the number of tumors in the lung, liver, and female reproductive tracts in the offspring of mice receiving the higher dose level of zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Reproductive and Developmental Toxicology Studies</h2>
<p class="First">Oral teratology studies in the rat and in the rabbit at doses up to 500 mg/kg/day revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> with zidovudine. Zidovudine treatment resulted in embryo/fetal toxicity as evidenced by an increase in the incidence of fetal resorptions in rats given 150 or 450 mg/kg/day and rabbits given 500 mg/kg/day. The doses used in the teratology studies resulted in peak zidovudine plasma concentrations (after one half of the daily dose) in rats 66 to 226 times, and in rabbits 12 to 87 times, mean steady-state peak human plasma concentrations (after one sixth of the daily dose) achieved with the recommended daily dose (100 mg every 4 hours). In an <span class="Italics">in vitro</span> experiment with fertilized mouse oocytes, zidovudine exposure resulted in a dose-dependent reduction in blastocyst formation. In an additional teratology study in rats, a dose of 3,000 mg/kg/day (very near the oral median lethal dose in rats of 3,683 mg/kg) caused marked maternal toxicity and an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. This dose resulted in peak zidovudine plasma concentrations 350 times peak human plasma concentrations. (Estimated AUC in rats at this dose level was 300 times the daily AUC in humans given 600 mg/day.) No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in this experiment at doses of 600 mg/kg/day or less.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Therapy with zidovudine has been shown to prolong survival and decrease the incidence of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> in patients with advanced HIV-1 disease and to delay disease progression in asymptomatic HIV-1-infected patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Combination Therapy:</span> Zidovudine in combination with other antiretroviral agents has been shown to be superior to monotherapy for one or more of the following endpoints: delaying <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, delaying development of AIDS, increasing CD4+ cell counts, and decreasing plasma HIV-1 RNA.</p>
<p>The clinical efficacy of a combination regimen that includes zidovudine was demonstrated in study ACTG320. This study was a multi-center, randomized, double-blind, placebo-controlled trial that compared zidovudine 600 mg/day plus EPIVIR<span class="Sup">®</span> 300 mg/day to zidovudine plus EPIVIR plus indinavir 800 mg three times daily. The incidence of AIDS-defining events or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was lower in the triple-drug–containing arm compared with the 2-drug–containing arm (6.1% versus 10.9%, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Monotherapy:</span> In controlled studies of treatment-naive patients conducted between 1986 and 1989, monotherapy with zidovudine, as compared with placebo, reduced the risk of HIV-1 disease progression, as assessed using endpoints that included the occurrence of HIV-1-related illnesses, AIDS-defining events, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. These studies enrolled patients with advanced disease  (BW002), and asymptomatic or mildly symptomatic disease in patients with CD4+ cell counts  between 200 and 500 cells/mm<span class="Sup">3</span> (ACTG016 and ACTG019). A survival benefit for monotherapy with zidovudine was not demonstrated in the latter 2 studies. Subsequent studies showed that the clinical benefit of monotherapy with zidovudine was time limited.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Patients</h2>
<p class="First">ACTG300 was a multi-center, randomized, double-blind study that provided for comparison of EPIVIR plus zidovudine to didanosine monotherapy. A total of 471 symptomatic, HIV-1-infected therapy-naive pediatric patients were enrolled in these 2 treatment arms. The median age was 2.7 years (range: 6 weeks to 14 years), the mean baseline CD4+ cell count was 868 cells/mm<span class="Sup">3</span>, and the mean baseline plasma HIV-1 RNA was 5.0 log<span class="Sub">10</span> copies/mL. The median duration that patients remained on study was approximately 10 months. Results are summarized in Table 10.</p>
<a name="table10a"></a><table width="75%">
<caption><span>Table 10. Number of Patients (%) Reaching a Primary Clinical Endpoint (Disease Progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>)</span></caption>
<col align="left" valign="top" width="48%">
<col align="center" valign="top" width="32%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="bottom">Endpoint</th>
<th class="Rrule" align="center">EPIVIR plus Zidovudine<br>(n = 236)</th>
<th class="Rrule" align="center">Didanosine<br>(n = 235)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (total)</td>
<td class="Rrule" align="center">15 (6.4%)</td>
<td class="Rrule" align="center">37 (15.7%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Physical growth failure</td>
<td class="Rrule" align="center">7 (3.0%)</td>
<td class="Rrule" align="center">6 (2.6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Central nervous system deterioration</td>
<td class="Rrule" align="center">4 (1.7%)</td>
<td class="Rrule" align="center">12 (5.1%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CDC Clinical Category C</td>
<td class="Rrule" align="center">2 (0.8%)</td>
<td class="Rrule" align="center">8 (3.4%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="center">2 (0.8%)</td>
<td class="Rrule" align="center">11 (4.7%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Prevention of Maternal-Fetal HIV-1 Transmission</h2>
<p class="First">The utility of zidovudine for the prevention of maternal-fetal HIV-1 transmission was demonstrated in a randomized, double-blind, placebo-controlled trial (ACTG076) conducted in HIV-1-infected pregnant women with CD4+ cell counts of 200 to 1,818 cells/mm<span class="Sup">3</span> (median in  the treated group: 560 cells/mm<span class="Sup">3</span>) who had little or no previous exposure to Zidovudine. Oral Zidovudine was initiated between 14 and 34 weeks of gestation (median 11 weeks of therapy) followed by IV administration of zidovudine during labor and delivery. Following birth, neonates received oral zidovudine syrup for 6 weeks. The study showed a statistically significant difference in the incidence of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in the neonates (based on viral culture from peripheral blood) between the group receiving zidovudine and the group receiving placebo. Of 363 neonates evaluated in the study, the estimated risk of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was 7.8% in the group receiving Zidovudine and 24.9% in the placebo group, a relative reduction in transmission risk of 68.7%. Zidovudine was well tolerated by mothers and infants. There was no difference in pregnancy-related adverse events between the treatment groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Zidovudine Capsules USP, 100mg are hard gelatin size '2' capsules with sky blue cap and white body, straight printed with 'ZVR 100'on both cap and body with black ink.</p>
<p>Zidovudine Capsules USP, 100mg are available as follows:</p>
<p>Bottles of 100 capsules (NDC 42799-403-01)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 20°C-25°C (68°F-77°F) [See USP Controlled Room Temperature].</p>
<p>Protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Advice for the Patient</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>:</span> Patients should be informed that the major toxicities of zidovudine are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. The frequency and severity of these toxicities are greater in patients with more advanced disease and in those who initiate therapy later in the course of their <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Patients should be informed that if toxicity develops, they may require transfusions or drug discontinuation. Patients should be informed of the extreme importance of having their blood counts followed closely while on therapy, especially for patients with advanced symptomatic HIV-1 disease <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>,<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>:</span> Patients should be informed that <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> with pathological changes, similar to that produced by HIV-1 disease, have been associated with prolonged use of zidovudine <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>,<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span>:</span> Patients should be informed that some HIV medicines, including zidovudine, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>,<a href="#S5.3"> Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.4"></a><p></p>
<p class="First"><span class="Underline">HIV-1/HCV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> Patients with HIV-1/HCV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be informed that hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.5"></a><p></p>
<p class="First"><span class="Underline">Use With Other Zidovudine-Containing Products:</span> Zidovudine should not be administered with combination products that contain zidovudine as one of their components (e.g., COMBIVIR [lamivudine and zidovudine] Tablets or TRIZIVIR [abacavir sulfate, lamivudine, and zidovudine] Tablets) [see <span class="Italics"><a href="#S5.5">Warnings and Precautions (5.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.6"></a><p></p>
<p class="First"><span class="Underline">Redistribution/Accumulation of Body Fat:</span> Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see<a href="#S5.7"> Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.7"></a><p></p>
<p class="First"><span class="Underline">Common Adverse Reactions:</span> Patients should be informed that the most commonly reported adverse reactions in adult patients being treated with zidovudine were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The most commonly reported adverse reactions in pediatric patients receiving zidovudine were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and digestive disorders. Patients also should be encouraged to contact their physician if they experience <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, or any other unexpected adverse events while being treated with zidovudine <span class="Italics">[see<a href="#S6"> Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.8"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions:</span> Patients should be cautioned about the use of other medications, including ganciclovir, interferon alfa, and ribavirin, which may exacerbate the toxicity of zidovudine <span class="Italics">[see<a href="#S7"> Drug Interaction (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.9"></a><p></p>
<p class="First"><span class="Underline">Pregnancy:</span> Pregnant women considering the use of zidovudine during pregnancy for prevention of HIV-1 transmission to their infants should be informed that transmission may still occur in some cases despite therapy. The long-term consequences of in utero and infant exposure to zidovudine are unknown, including the possible risk of cancer <span class="Italics">[see<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>.</p>
<p>HIV-1-infected pregnant women should be informed not to breastfeed to avoid postnatal transmission of HIV to a child who may not yet be infected <span class="Italics">[see<a href="#S8.3"> Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.10"></a><p></p>
<p class="First"><span class="Underline">Information About HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> Zidovudine is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using zidovudine. Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<ul>
<li>Do not share needles or other injection equipment.</li>
<li>Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</li>
<li>Do not have any kind of sex without protection. Always practice safe sex by using a latex or polyurethane condom or other barrier method to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
<li>Do not breastfeed. Zidovudine is excreted in human breast milk. Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
<p>Patients should be informed to take all HIV medications exactly as prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1.11"></a><p></p>
<p class="First"><span class="Bold">Disclaimer:</span></p>
<p><span class="Bold">Other brands listed viz. COMBIVIR, EPIVIR, and TRIZIVIR are the registered trademarks of their respective owners and are not trademarks of Cipla Ltd or Edenbridge Pharmaceuticals, LLC.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Manufactured by:</span><br>Cipla Ltd. Verna, Goa INDIA</p>
<p><span class="Bold">For: </span><br>Edenbridge Pharmaceuticals, LLC<br>Parsippany, NJ  07054</p>
<p>Iss. 12/11</p>
<p>IL63A</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 Bottle Label</span></p>
<p><span class="Bold">NDC 42799-403-01</span></p>
<p><span class="Bold">Zidovudine<br>Capsules, USP</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">100 Capsules<br>Rx only</span></p>
<p><span class="Bold Italics">Edenbridge<br>Pharmaceuticals</span></p>
<div class="Figure"><img alt="Principal Display Panel - 100 Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3c2532a-5880-4d52-b2a1-2e6d4dbd6021&amp;name=zidovudine-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZIDOVUDINE 		
					</strong><br><span class="contentTableReg">zidovudine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42799-403</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Zidovudine</strong> (Zidovudine) </td>
<td class="formItem">Zidovudine</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE, BLUE (SKY BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42799-403-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078349</td>
<td class="formItem">04/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Edenbridge Pharmaceuticals, LLC
							(948715060)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cipla Limited</td>
<td class="formItem"></td>
<td class="formItem">650072015</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c2002324-a271-4402-8f39-8cdbcfd61080</div>
<div>Set id: a3c2532a-5880-4d52-b2a1-2e6d4dbd6021</div>
<div>Version: 1</div>
<div>Effective Time: 20120401</div>
</div>
</div> <div class="DistributorName">Edenbridge Pharmaceuticals, LLC</div></p>
</body></html>
